Daptomycin in experimental murine pneumococcal meningitis by Mook-Kanamori, Barry B et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Daptomycin in experimental murine pneumococcal meningitis
Barry B Mook-Kanamori1, Mark S Rouse1, Cheol-In Kang1, Diederik van de 
Beek1, James M Steckelberg1 and Robin Patel*1,2
Address: 1Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA and 2Division 
of Clinical Microbiology, Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN, USA
Email: Barry B Mook-Kanamori - mook.barry@mayo.edu; Mark S Rouse - rouse.mark@mayo.edu; Cheol-In Kang - collacin@hotmail.com; 
Diederik van de Beek - vandebeek.diederik@mayo.edu; James M Steckelberg - steckelberg.james@mayo.edu; 
Robin Patel* - patel.robin@mayo.edu
* Corresponding author    
Abstract
Background: Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for
treatment of pneumococcal meningitis. We determined the activity of daptomycin versus
vancomycin, with dexamethasone as an adjuvant, in a murine model of pneumococcal meningitis.
Methods:  Ninety-six 25–30 gram mice were inoculated intracisternally with serotype 3
Streptococcus pneumoniae modified by the integration of a luminescent lux operon. All mice were
treated with either dexamethasone 1 mg/kg intraperitoneally every 6 hours alone or in
combination with either vancomycin or daptomycin, also administered intraperitoneally. Serum
antimicrobial concentrations were selected to approximate those achieved in humans. Following
treatment, bioluminescence and cerebrospinal fluid (CSF) bacterial concentrations were
determined. Caspase-3 staining was used to assess apoptosis on brain histopathology.
Results: Sixteen hours post intracisternal inoculation, bacterial titers in CSF were 6.8 log10 cfu/ml.
Amongst the animals given no antibiotic, vancomycin 50 mg/kg at 16 and 20 hours or daptomycin
25 mg/kg at 16 hours, CSF titers were 7.6, 3.4, and 3.9 log10 cfu/ml, respectively, at 24 hours post
infection (p-value, < 0.001 for both vancomycin or daptomycin versus no antibiotic); there was no
significant difference in bactericidal activity between the vancomycin and daptomycin groups (p-
value, 0.18). CSF bioluminescence correlated with bacterial titer (Pearson regression coefficient,
0.75). The amount of apoptosis of brain parenchymal cells was equivalent among treatment groups.
Conclusion: Daptomycin or vancomycin, when given in combination with dexamethasone, is
active in the treatment of experimental pneumococcal meningitis.
Background
Pneumococcal meningitis is associated with high mortal-
ity and morbidity rates [1]. Patients with suspected or
proven pneumococcal meningitis should receive immedi-
ate empirical therapy consisting of a combination of a
third-generation cephalosporin and vancomycin, plus
dexamethasone [1].
Daptomycin, a lipopeptide antibiotic which has excellent
activity against a broad range of Gram-positive microor-
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ganisms, including penicillin and cephalosporin resistant
pneumococci [2,3], could be an alternative to vancomycin
for treatment of pneumococcal meningitis. Rapid bacteri-
cidal activity, without lysis and limited inflammatory
response, makes daptomycin an attractive possibility for
the treatment of multidrug-resistant pneumococcal men-
ingitis [2,3]. No published animal studies have evaluated
the combination of daptomycin plus dexamethasone for
treatment of experimental pneumococcal meningitis.
In this study, we used a murine model of pneumococcal
meningitis to compare the activity of daptomycin with




Streptococcus pneumoniae A 66.1 serotype 3 rendered biolu-
minescent by integration of a modified lux operon into its
chromosome (S. pneumoniae Xen 10, Xenogen Corpora-
tion, Alameda, CA) was studied. This strain has been pre-
viously shown to be as virulent as its parent strain [4].
Serotype 3 is one of the most common pneumococcal
serotypes causing community-acquired bacterial meningi-
tis in adults [5]. Bacteria were incubated in Todd-Hewitt
broth (THB) at 37°C in 5% CO2 to an OD620 of 0.4 and
subsequently rinsed in phosphate buffered saline (PBS)
and centrifuged to yield a final bacterial concentration of
5 × 1010 colony forming units (cfu)/ml. The exact number
of cfu in the inoculum was determined retrospectively by
growth of serial dilutions of the inoculum on blood agar
plates.
In vitro studies
The MBC and MIC of daptomycin and vancomycin (with
and without dexamethasone), and of penicillin, against S.
pneumoniae  Xen10 were determined using methods
described by the Clinical Laboratory Standards Institute
[6]. Time kill studies to determine the bactericidal activity
of daptomycin 1 μg/ml or vancomycin 2 μg/ml alone and
in combination with dexamethasone 100 μg/ml were per-
formed as described by Anhalt and Washington [8].
Pharmacokinetics of vancomycin and daptomycin
The 30 minute serum concentration of vancomycin or
daptomycin in 25–30 gram immunocompetent hairless
mice (Charles River Laboratories, Wilmington, MA) was
determined following intraperitoneal injection of 40, 50
and 60 mg/kg vancomycin or 20, 30, 40 and 50 mg/kg
daptomycin, respectively. Pharmacokinetic profiles were
determined by injecting 50 mg/kg vancomycin or 25 mg/
kg daptomycin intraperitoneally and obtaining serum
samples 30, 60, 120, 180 and 240 minutes post injection.
Drug activity was measured using a microbiological assay
technique. Standard curves for serum drug level determi-
nation were performed by making drug dilutions in
pooled mouse serum (Innovative Research, Incorporated,
Southfield, MI). The reporter bacteria for the vancomycin
and daptomycin bioassays were Bacillus subtilis and Micro-
coccus luteus, respectively. Zones of growth inhibition were
measured to the nearest millimeter. The detection limit
for both drugs was 0.5 μg/ml.
Murine meningitis model
This study was approved by the Institutional Animal Care
and Use Committee of the Mayo Clinic, Rochester, Min-
nesota. Ninety-six 25–30 gram immunocompetent hair-
less mice were divided into three treatment groups.
Sixteen hours prior to treatment, mice were anesthetized
using ketamine and xylazine (45 mg/kg and 5 mg/kg I.M.,
respectively) and 3 × 104 cfu of bacteria in a 20 μl volume
were inoculated into the cisterna magna. The time of treat-
ment was selected as the latest time point at which antimi-
crobial treatment could realistically lead to recovery.
Treatment was initiated by dividing all inoculated mice
into three groups and treating with 1 mg/kg dexametha-
sone alone, or in combination with 25 mg/kg daptomycin
or 50 mg/kg vancomycin. At 22 hours post infection an
additional dose of dexamethasone 1 mg/kg was adminis-
tered. At 20 hours post infection an additional dose of
vancomycin 50 mg/kg was given to the vancomycin-
treated animals. Mice not receiving vancomycin at 20
hours were injected with an equal volume of saline. At 16,
20, and 24 hours post infection, 8, 40 and 48 animals,
respectively were re anesthetized and cerebrospinal fluid
(CSF) was collected by way of puncture from the cisterna
magna (using a 28 G 1/2 needle 0.3 × 13 mm from BD
Microlance). CSF white-blood cell count was determined
and bacterial burden was quantified in CSF by plating
serial 10-fold dilutions in sterile isotonic saline onto
blood agar plates. Results were expressed as log10 cfu/ml;
the detection limit was 20 cfu/ml of CSF. Following col-
lection of CSF, animals were euthanized with a lethal dose
of pentobarbital, their brains collected and placed in 10%
neutral buffered formalin. There was no mortality (prior
to tissue harvest).
Imaging studies
In vivo bioluminescence imaging was performed using
the Lumazone Imaging System (1002 FE series; Roper Sci-
entific, Tucson, Arizona) at 16, 20 and 24 hours post
infection. Animals were sedated with ketamine plus xyla-
zine, placed in an imaging box without restraint, and
imaged for a maximum of 10 minutes at 4 × 4 binning res-
olution. Luminescence was quantified in photons/sec;
correlation analysis with bacterial titers was performed.
Histopathology studies
Serial coronal sections of formalin-fixed whole brain were
prepared. Brain was routinely processed, embedded inBMC Infectious Diseases 2009, 9:50 http://www.biomedcentral.com/1471-2334/9/50
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paraffin, sectioned at approximately 5–6 μm, and stained
with hematoxylin and eosin (H&E), cresyl echt violet for
Nissl substance, and a rabbit anti-human cleaved caspase-
3 HRP antibody (Seventh Wave Laboratories, Chester-
field, MO), for apoptosis. The whole brain sections were
scored for inflammation, neuronal necrosis, and paren-
chymal apoptosis by an independent veterinary patholo-
gist (Dr. Ewing, Genzyme Corporation, Cambridge, MA).
Statistics
Bacterial concentrations between treatment groups at
each time point were compared using the student t-test.
Correlation analysis between log10 bacterial CSF titers and
log10 photons/second was calculated using SPSS statistical
software. For inflammation, neuronal necrosis, and apop-
tosis scores, statistical analysis included a nonparametric
Kruskal-Wallis test followed by a Dunn's test comparing
all treatment groups using a confidence level of 95%.
Results
In vitro studies
The MIC/MBC of daptomycin, vancomycin, penicillin
and dexamethasone were 0.06/0.125, 0.125/0.25, 0.03/
0.06 and > 128/> 128 respectively. The in vitro bactericidal
activity of daptomycin and vancomycin was not affected
by 100 μg/ml of dexamethasone (Figure 1).
Pharmacokinetics of vancomycin and daptomycin
The highest dose of daptomycin currently approved by the
FDA is 6 mg/kg q.d. intravenously, corresponding to a
serum Cmax of 90–100 μg/ml. In mice, 25 mg/kg of dapto-
mycin intraperitoneally was found to best approximate
the human Cmax and used for the remainder of the experi-
ments (Figure 2). A 30 minute daptomycin concentration
of 127 μg/ml decreased to 16 μg/ml after 4 hours. Vanco-
mycin was given at a dose of 50 mg/kg which yielded a
level of 55 μg/ml at 30 minutes, thereafter rapidly declin-
Time kill assay Figure 1
Time kill assay. Bactericidal activities of daptomycin (1 μg/ml) or vancomycin (2 μg/ml) are not affected by dexamethasone 
(100 μg/ml). DP, daptomycin; VN, vancomycin; DX, dexamethasone.
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ing to < 0.5 μg/ml at 3 hours (Figure 2). Because of its
short half-life, vancomycin was given every 4 hours,
whereas daptomycin was given once. Dexamethasone was
given every 6 hours.
Murine meningitis model
Daptomycin and vancomycin, given in combination with
dexamethasone, resulted in similar bactericidal activity in
vivo. Mice treated with dexamethasone alone showed an
increase in CSF pneumococcal concentration after 8 hours
(+ 1.31 log10 cfu/ml), but not after 4 hours (- 0.02 log10
cfu/ml) of treatment (Table 1, Figure 3). Four hours after
a single treatment with either daptomycin or vancomycin
accompanied by 1 mg/kg of dexamethasone, bacterial tit-
ers dropped by 1.33 and 0.43 log10 respectively (p-value:
0.004 and 0.36, respectively, versus no antibiotic). After 8
hours, daptomycin-/dexamethasone- and vancomycin-/
dexamethasone-treated mice showed a reduction of bacte-
rial titer of 2.33 log10 and 2.82 log10 versus no antibiotic
(p-value < 0.001 for both groups). The antibiotic treat-
ment groups differed significantly at 4 (p-value 0.02 dap-
tomycin versus vancomycin), but not at 8 (p-value 0.18,
daptomycin versus vancomycin) hours. At 8 hours, 2/16
of the daptomycin-/dexamethasone-treated mice and 4/
16 of the vancomycin-/dexamethasone-treated mice had
bacterial concentrations below the limit of detection.
White blood cell quantification in the CSF appeared to be
influenced by blood contamination during sample collec-
tion. No significant difference between treatment groups
was observed at any time point (data not shown).
Imaging studies
Due to technical problems with the imaging system, 70 of
96 (73%) mice were imaged. Forty-six mice had lumines-
cence lower than the detection limit and were not
included in the correlation analysis. Amongst the 24 ani-
mals with luminescence above the detection limit, imag-
ing findings were consistent with meningitis without
infection of other sites (Figure 4). Imaging studies
revealed a correlation (Pearson's R) of 0.75 between CSF
bacterial titer and photons per second (P < 0.0001). The
luminescence detection limit corresponded to 4.0 log10
cfu/ml or 5.0 log10 photons/sec, when imaging for 10
minutes at 4 × 4 binning resolution (Figure 5).
Histopathology studies
Mice intracisternally inoculated with S. pneumoniae had
minimal to mild, focal to multifocal meningeal infiltrates
of predominantly neutrophils admixed with small num-
bers of macrophages and small lymphocytes at one or
more levels of the brain at all time points examined (Fig-
ure 6). Inflammatory cell infiltrates displayed mild multi-
focal apoptosis. The amounts of inflammation and
apoptosis of brain parenchymal cells were equivalent
among treatment groups (data not shown).
Some of the mice had involvement of the brain paren-
chyma primarily limited to the brainstem. The involve-
Serum antibiotic concentration after a single intraperitoneal dose of vancomycin (50 mg/kg) or daptomycin (25 mg/kg) Figure 2
Serum antibiotic concentration after a single intraperitoneal dose of vancomycin (50 mg/kg) or daptomycin 
(25 mg/kg).
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ment featured focal neutrophilic encephalitis or abscess
formation associated with variable numbers of bacterial
cocci, neuronal necrosis or loss, hemorrhage, and vacu-
olation of the neuropil. The density of bacterial cocci in
some of the foci of encephalitis of antibiotic-treated mice
appeared to be lower than that of the pre-treatment or
dexamethasone only treated mice. Neuronal necrosis was
not observed in any other areas of the brain. The incidence
of encephalitis in the dexamethasone alone, daptomycin
and vancomycin groups at 20 hours was 4/8 (50%), 4/14
(29%), and 3/15 (20%), respectively (P > 0.05). The inci-
dence of encephalitis in the dexamethasone alone, dapto-
mycin and vancomycin groups at 24 hours was 5/10
(50%), 2/15 (13%), and 5/14 (36%), respectively (P >
0.05).
Discussion
At drug serum concentrations approximating the human
Cmax, daptomycin and vancomycin were both highly
effective at killing S. pneumoniae in CSF, when given in
Concentrations of Streptococcus pneumoniae in cerebrospinal fluid Figure 3
Concentrations of Streptococcus pneumoniae in cerebrospinal fluid. Concentration of S. pneumoniae in cerebrospinal 
fluid after 0, 4 and 8 hours of intraperitoneal injection of dexamethasone (administered at 0 and 6 hours) alone (DX), daptomy-
cin (administered at 0 hours) and dexamethasone (administered at 0 and 6 hours) (DX/DP), or vancomycin (administered at 0 


















































Table 1: Mean bacterial concentration at time of treatment (0 hours ± SD, pooled data from all three groups), and after 4 or 8 hours of 







Dexamethasone -0.02 ± 1.49 1.31 ± 1.16
Dexamethasone/daptomycin* 6.24 ± 0.86 -1.33 ± 1.24 -2.33 ± 1.51
Dexamethasone/vancomycin# -0.43 ± 1.49 -2.82 ± 1.36
*Daptomycin 25 mg/kg intraperitoneally, administered at 0 hours.
#Vancomycin 50 mg/kg intraperitoneally, administered at 0 and 4 hours.BMC Infectious Diseases 2009, 9:50 http://www.biomedcentral.com/1471-2334/9/50
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combination with dexamethasone. Daptomycin was
more rapidly bactericidal than vancomycin, resulting in a
significantly lower bacterial CSF titer after just four hours
of treatment, although after eight hours, CSF bacterial
counts did not differ significantly. In vitro time-kill studies
demonstrated equivalent bactericidal activity of daptomy-
cin and vancomycin.
Four studies of daptomycin treatment of experimental
meningitis have been reported [8-11]. Using a rabbit men-
ingitis model, Cottagnoud et al. showed a 6% (of serum
drug levels) penetration of daptomycin across inflamed
meninges, and better activity than ceftriaxone plus vanco-
mycin against penicillin-resistant pneumococcal strains
[8]. A follow-up study showed that daptomycin was asso-
ciated with negligible release of [3H]choline (a marker of
cell wall lysis) compared with ceftriaxone treatment [10].
Similarly, Gerber et al. reported bactericidal activity in a
rabbit model of Staphylococcus aureus meningitis; they also
observed that the degree of meningeal inflammation
affected the penetration of daptomycin across the blood-
brain-barrier [9]. Finally, Grandgirard et al. compared
daptomycin with ceftriaxone in an experimental model of
rat pneumococcal meningitis; daptomycin more effi-
ciently cleared pneumococci from CSF than did ceftriax-
one, reduced the concentration of matrix
metalloproteinase-9 concentration in CSF 40 hours after
infection, and prevented development of cortical injury
[11]. None of these studies used dexamethasone as adju-
vant treatment, which has become standard practice in the
treatment of human bacterial meningitis in adults in
developed countries, and which may impact the activity of
antimicrobial agents in meningitis [12,13].
The pharmacokinetic and pharmacodynamic properties
of both vancomycin and daptomycin have been described
in previous studies, and have been shown to vary consid-
erably between animal models. Based on the pharmacok-
inetic characteristics in our mouse meningitis model, our
best approximation of human pharmacokinetic parame-
ters was achieved by giving daptomycin once and vanco-
mycin twice, four hours apart. Vancomycin was rapidly
cleared from the serum of the mice in our study. Thus, at
the four hour time point, all treatment groups had
received a single dose of antimicrobial. At the 8 hour time
point, the vancomycin treated group had received two
doses of vancomycin, and all mice had received a second
dose of dexamethasone. Although pharmacokinetic
approximation is clearly a limitation of animal studies,
careful conclusions about the efficacy of both drugs in our
model can still be made.
The use of bioluminescent S. pneumoniae and the Luma-
zone imaging system allow for real-time, non-invasive
determination of bacterial activity in CSF as a measure of
infection and treatment thereof, thus limiting the need for
multiple invasive CSF withdrawals per animal, and reduc-
ing the number of required animals per treatment group.
Representative bioluminescence images Figure 4
Representative bioluminescence images. Representative bioluminescence images taken using the Lumazone Imaging Sys-
tem after 0, 4 and 8 hours of treatment with dexamethasone (administered at 0 and 6 hours) alone (DX), daptomycin (admin-
istered at 0 hours) and dexamethasone (administered at 0 and 6 hours) (DX/DP), or vancomycin (administered at 0 and 4 
hours) and dexamethasone (administered at 0 and 6 hours) (DX/VN). Photons/second are displayed on a calibrated color 
overlay (blue = low, through red = high).
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However, the bioluminescent detection limit corre-
sponded to 4 log10 cfu/ml, almost 2 log10 higher than the
detection limit using quantitative cultures (2.3 log10 cfu/
ml), making luminescent imaging most useful during the
initial phase of the infection. Although bioluminescent
data was not obtained on all animals in this study, ani-
mals with the complete spectrum of bacterial CSF concen-
trations were imaged. Because bioluminescence measured
the activity of bacteria rather than actual bacterial killing,
no definite conclusions can be inferred regarding the bac-
tericidal versus bacteriostatic effects of the antimicrobial
treatment regimens. Nevertheless, in vivo photonic imag-
ing remains a relevant method for studying the pathogen-
esis and pathophysiology of bacterial meningitis.
Clinical trials of daptomycin for the treatment of Gram-
positive bacteremia, endocarditis, and complicated skin
and skin-structure infections have yielded favorable
results [2,3,14]. A case report of successful treatment of
methicillin-resistant S. aureus meningitis with daptomy-
cin has been reported [15]. In vitro and animal model
studies have shown diminished inflammatory response to
infections treated with daptomycin compared with com-
parators [13,16]. The lack of noted differences in inflam-
mation among treatment groups that had statistically
significantly lower mean bacterial titers (i.e., daptomycin
and vancomycin groups compared to no antibiotic
groups) may be related to the relatively early time point of
collection of brains, and/or to the concomitant adminis-
tration of dexamethasone. Histopathologic evaluation of
brains at later time points may be required to appreciate
treatment group differences in inflammation. Further ani-
mal studies are necessary to investigate the effects of dap-
tomycin/dexamethasone treatment on outcome
parameters such as CSF inflammation, brain tissue dam-
age and residual neurological deficit, in the context of dex-
amethasone treatment.
Conclusion
Daptomycin or vancomycin, when given in combination
with dexamethasone, is active in the treatment of experi-
mental pneumococcal meningitis. The observed bacteri-
cidal activity in this study is consistent with previous
studies and provides support for future evaluation of dap-
Correlation between bacterial cerebrospinal fluid concentration and chemiluminescence (Pearson's R, 0.75; P < 0.0001) Figure 5
Correlation between bacterial cerebrospinal fluid concentration and chemiluminescence (Pearson's R, 0.75; P 
< 0.0001).
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tomycin as an alternative to vancomycin in the treatment
of bacterial meningitis.
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